Merck potential purchase of Seagen said unlikely by earnings date - report

Merck's (NYSE:MRK) potential $40 billion acquisition of Seagen (NASDAQ:SGEN) is not likely to happen ahead of the pharma co.'s earnings later this month, though talks still remain on track.